Q-omics provides the consensus-scored PLA2G4E profile across patient tissues and cancer cell-line models. PLA2G4E expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLA2G4E is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, PLA2G4E RNA expression shows 11,028 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, COAD, and ESCA as cancer lineages where PLA2G4E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G4E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G4E survival associations across molecular data types. PLA2G4E RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G4E RNA expression–survival associations across cancer types. High PLA2G4E expression shows unfavorable associations in KIRC, KIRP, UVM and SKCM, but favorable associations in SCLC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLA2G4E RNA expression.
This table summarizes PLA2G4E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLA2G4E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G4E shows lower tumor expression in THCA, LUAD and KICH and higher tumor expression in COAD, CHOL and READ. The COAD box plot shows higher PLA2G4E RNA expression in tumor versus normal tissue (log2 FC = +0.286, t-test p < 0.001).
This table shows molecular features associated with PLA2G4E in patient tissues and cancer cell lines. In patient samples, PLA2G4E shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G4E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
